Barclays Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $56.00

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective reduced by Barclays from $58.00 to $56.00 in a research report report published on Friday,Benzinga reports. Barclays currently has an overweight rating on the specialty pharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective (up from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Truist Financial set a $55.00 price objective on Collegium Pharmaceutical in a research note on Wednesday. Finally, Needham & Company LLC lifted their price objective on Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.80.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $45.54 on Friday. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $50.79. The company has a market capitalization of $1.44 billion, a P/E ratio of 28.29 and a beta of 0.60. The stock has a 50 day moving average of $46.23 and a two-hundred day moving average of $38.61. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The business had revenue of $135.55 million for the quarter. As a group, equities analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insiders Place Their Bets

In related news, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total transaction of $171,659.50. Following the transaction, the director owned 52,629 shares in the company, valued at $2,475,141.87. This represents a 6.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Scott Dreyer sold 17,600 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the sale, the executive vice president directly owned 103,613 shares in the company, valued at approximately $4,991,038.21. This represents a 14.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 51,250 shares of company stock valued at $2,235,352. 2.51% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of large investors have recently modified their holdings of the stock. Federated Hermes Inc. grew its stake in shares of Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 350 shares during the last quarter. CWM LLC boosted its position in Collegium Pharmaceutical by 453.9% in the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 1,153 shares during the last quarter. Hantz Financial Services Inc. boosted its position in Collegium Pharmaceutical by 137.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 993 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Collegium Pharmaceutical by 744.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after buying an additional 2,190 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of Collegium Pharmaceutical by 368.9% during the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock worth $82,000 after acquiring an additional 2,169 shares during the last quarter.

Trending Headlines about Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Collegium issued 2026 financial guidance that topped consensus on revenue. Management expects product revenues of $805M–$825M (vs. consensus ~$782.9M) and adjusted EBITDA of $455M–$475M; Jornay PM net revenue is guided to $190M–$200M. This stronger-than-expected top‑line and profitability outlook is a clear positive catalyst. Collegium Provides 2026 Financial Guidance and Business Update
• Positive Sentiment: Needham raised its price target from $48 to $56 and maintained a “buy” rating, implying roughly 23% upside from the current level — a supportive analyst endorsement that can attract buyers. Benzinga TickerReport
• Neutral Sentiment: Barclays trimmed its price target slightly (from $58 to $56) but kept an “overweight” rating — a mixed signal that reduces upside expectations a bit while still indicating conviction in the name. Benzinga
• Neutral Sentiment: A broader industry piece highlighting branded pharmaceuticals and peer Q3 results mentions the group context for names like Collegium; useful for benchmarking but not specific company news. MSN: Branded pharmaceuticals stocks Q3 results
• Negative Sentiment: Zacks downgraded Collegium from “strong-buy” to “hold,” which may prompt some profit‑taking or limit fresh inflows from investors who follow Zacks ratings. Zacks TickerReport

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.